Will Pfizer Sweeten the Offer?
Ranjith Gopinathan, Life Sciences Programme Manager at Frost & Sullivan, comments on Pfizer’s possible takeover of Astra Zeneca
“We are witnessing a new surge in M&A activities in Big Pharma, as large companies are now seeking to strengthen their core business and divest the weak ones.
For instance, Pfizer is already in talks with AstraZeneca for an outright acquisition. This strategy ties in with Pfizer’s historical M&As, which include its $68 billion acquisition of Wyeth in 2009 due to the company’s strong biologics pipeline particularly in Central Nervous System disorders.
The key driver for the latest offer is AstraZeneca’s strong pipeline in immunotherapies. Moreover, it would enhance Pfizer’s offering in oncology, cardiovascular and diabetes. It would also boost its footprint in emerging markets. Although AstraZeneca has rejected Pfizer’s offer twice, the reason for this seems to be a price negotiation tactic.
Furthermore, there is a strong possibility that Pfizer would move its base to the UK for tax saving purposes. In fact, avoiding a higher tax in the US could be the major reason behind Pfizer’s latest move. Although immuno-oncology is a highly lucrative segment for pharma companies, it would face stiff competition from companies such as BMS, Merck and Roche with late-stage drugs in the pipeline.
Many Big Pharma firms are sitting on huge cash piles and are hunting for acquisition targets with promising drug pipeline. One possible outcome of this rapid consolidation is the augmented bargaining power of big pharma against payers and government. In theory, mergers and asset swaps are expected to improve efficiencies and productivity of the drug development process. However, integration, post M&A has never been an easy task.
Now, the billion dollar question is, would Pfizer sweeten its offer to clinch the deal?”
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance